3-(4-bromophenyl)-3-methyl-butyraldehyde | 92846-14-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-bromophenyl)-3-methyl-butyraldehyde
• 英文别名: β-(4-Bromphenyl)-isovaleraldehyd；3-(4-Bromophenyl)-3-methylbutanal；3-(4-bromophenyl)-3-methylbutanal
• CAS: 92846-14-5
• 化学式: C₁₁H₁₃BrO
• 分子量: 241.128
• InChiKey: QTGCEHRNIMEHKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-(4-bromophenyl)-3-methylbutanoic acid 在 氯化亚砜 、 lithium tri-t-butoxyaluminum hydride 作用下， 生成 3-(4-bromophenyl)-3-methyl-butyraldehyde
  参考文献：
  名称：

  Ruechardt,C.; Eichler,S., Chemische Berichte, 1962, vol. 95, p. 1921 - 1942

  摘要：

  DOI：

文献信息

• INHIBITORS OF BETA-SECRETASE
  申请人：CACATIAN Salvacion

  公开号：US20110071126A1

  公开（公告）日：2011-03-24

  The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.

  本发明涉及下述结构式所代表的化合物或其药学上可接受的盐。同时还描述了该化合物的药物组合物和使用方法。
• BIARYL DERIVATIVE AS GPR120 AGONIST
  申请人：LG Chem, Ltd.

  公开号：EP3239143A2

  公开（公告）日：2017-11-01

  The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  本发明涉及一种由化学式1表示的生物芳基衍生物、生产该生物芳基衍生物的方法、包含该生物芳基衍生物的药物组合物以及该生物芳基衍生物的用途，由化学式1表示的生物芳基衍生物作为GPR120激动剂，促进胃肠道中GLP-1的生成、从巨噬细胞、胰腺细胞等的抗炎活性中降低肝脏、肌肉等的胰岛素抵抗，并可有效用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝、脂肪肝和骨质疏松症。
• Biaryl derivative as GPR120 agonist
  申请人：LG CHEM, LTD.

  公开号：US11261186B2

  公开（公告）日：2022-03-01

  Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

  具有化学式1的化合物，制备所述化学式1化合物的方法，包含所述化合物的药物组合物，以及将其用作一种GPR120激动剂，用于预防或治疗炎症或代谢性疾病，如糖尿病、糖尿病并发症、肥胖症、非酒精性脂肪肝病、脂肪肝病和骨质疏松症。
• Ruechardt,C.; Eichler,S., Chemische Berichte, 1962, vol. 95, p. 1921 - 1942
  作者：Ruechardt,C.、Eichler,S.

  DOI：——

  日期：——